الملخص
Fundamento: La preeclampsia es un estado de vasoconstricción generalizado asociado a la disfunción del epitelio vascular en vez de vasodilatación propia del embarazo, caracterizada por la hipertensión proteinuria a partir de la semana 20, acompañada a veces de edemas; asimismo constituye un peligro de salud para la madre y el feto. El tratamiento clínico tradicional utiliza fármacos antihipertensivos por vía oral, entre los que se mencionan el labetalol y nifedipino de liberación prolongada. Objetivo: Analizar la efectividad del labetalol y del nifedipino como tratamiento antihipertensivo relacionado con preeclampsia. Metodología: Se recurrió a fuentes de consulta encontradas en Google Scholar, Science Direct, SciELO, Pubmed, Medes y Elsevier. De 211 fuentes se seleccionaron 31 de acuerdo con criterios de inclusión y exclusión. Conclusiones: Por consenso se ha determinado que en la mayor parte de fuentes de consulta el nifedipino por vía oral es más efectivo que el labetalol en el tratamiento de la preeclampsia.
Background: Pre-eclampsia is a generalized vasoconstriction state associated with vascular epithelial dysfunction rather than the vasodilation characteristic of pregnancy, characterized by proteinuric hypertension from the 20th week of pregnancy, sometimes associated with edema; it also causes health risks to the mother and fetus. Traditional clinical treatment uses oral antihypertensive drugs, among these labetalol and extended-release nifedipine are included. Objective: To analyze the efficacy of labetalol and nifedipine as an antihypertensive treatment in pre-eclampsia. Methodology: Reference sources found in Google Scholar, Science Direct, SciELO, Pubmed, Medes and Elsevier were used. Out of 211 sources, 31 were selected according to inclusion and exclusion criteria. Conclusions: It has been determined by majority consensus that oral nifedipine is more effective than labetalol in pre-eclampsia treatment.
الموضوعات
Humans , Pre-Eclampsia , Nifedipine , Hypertension, Pregnancy-Induced , Labetalolالملخص
OBJECTIVES@#The use of anticholinergic drugs in the elderly may lead to negative events such as falls, delirium, urinary retention and cognitive decline, and the higher the number of anticholinergic drugs use, the more such negative events occur. This study aims to analyze the risk factors associated with the prescription of total anticholinergic drugs in elderly outpatients and evaluate the rationality of anticholinergic drugs, and to provide a reference for reducing the adverse effects of anticholinergic drugs.@*METHODS@#A list of drugs with anticholinergic activity based on the Beers criteria was established. The basic information (such as age and gender), clinical diagnosis, and medications of elderly outpatient were extracted from hospital electronic medical records, and the Anticholinergic Cognitive Burden (ACB) Scale was used to calculate the anticholinergic burden for each patient. Logistic regression analysis was used to identify the potential risk factors for the occurrence of problems such as multiple medication and insomnia.@*RESULTS@#A total of 1 840 prescriptions for elderly patients were reviewed. Of these patients, ACB score was more than or equal to 1 in 648 (35.22%) patients. Number of prescription medication (95% CI: 1.221 to 1.336) and insomnia (95% CI: 3.538 to 6.089) were independent factors affecting ACB scores (both P<0.01). Medications for patients of ACB scores were most commonly treated with the central nervous system drugs (such as alprazolam and eszopiclone) and for the cardiovascular system drugs (such as metoprolol and nifedipine).@*CONCLUSIONS@#There is a high rate of ACB drugs use in geriatric patients, and the clinical focus should be on multiple medication prescriptions, especially on the central nervous system drugs (such as alprazolam and eszopiclone) and cardiovascular system drugs (such as metoprolol and nifedipine). The prescription review should be emphasized to reduce adverse reactions to anticholinergic drugs in elderly patients.
الموضوعات
Humans , Aged , Cholinergic Antagonists/adverse effects , Outpatients , Metoprolol , Alprazolam , Eszopiclone , Nifedipine , Sleep Initiation and Maintenance Disorders , Risk Factorsالملخص
RESUMEN: Este reporte de caso muestra un paciente atendido en el Postítulo de Periodoncia de la Facultad de Odontología de la Universidad de Chile con diagnóstico de Agrandamiento Gingival influenciado por ciclosporina y nifedipino. El abordaje terapéutico consideró la fase sistémica, la fase higiénica con el tratamiento periodontal no quirúrgico para lograr la eliminación de la infección periodontal antes y después de la fase quirúrgica, y la fase de terapia de soporte periodontal. Se logró así la eliminación de los agrandamientos gingivales influenciados por ciclosporina y nifedipino.
ABSTRACT: This case report shows a patient attended in the Postgraduate Periodontics Program at the Faculty of Dentistry of the University of Chile with a diagnosis of Gingival Enlargement influenced by cyclosporine and nifedipine. The therapeutic approach considered the systemic phase, the hygienic phase with the non-surgical periodontal treatment to achieve the elimination of the periodontal infection before and after the surgical phase, and the phase of periodontal support therapy. Thus, the elimination of gingival enlargements influenced by cyclosporine and nifedipine was achieved.
الموضوعات
Humans , Male , Adult , Nifedipine/adverse effects , Cyclosporine/adverse effects , Gingival Overgrowth/chemically induced , Gingival Overgrowth/therapyالملخص
Abstract Objectives: to evaluate the effects of nifedipine with tocolysis under maternal and fetal parameters. Methods: a cohort study with 40 pregnant women admitted at a high-risk pregnancy ward to inhibit premature labor between September/2010 to May/2012. Nifedipine was used as a 20mg sublingual attack dose and maintained 20mg every six and eight hours orally. The variables of the analysis were fetal heart rate (FHR), maternal heart rate (MHR), systolic blood pressure (SBP) and diastolic blood pressure (DBP), and amniotic fluid index (AFI). All the variables were evaluated prior to administrating nifedipine and approximately after 6 hours and every 24 hours, until hospital discharge. Results: there were no modification of the FHR (p=0.48) and the SBP (p=0.29). The MHR increased after 24 hours, but with no statistical difference (p=0.08), returning to similar levels as at admission within 48 hours. The DBP decreased at 6 (p=0.04) to 72 hours, being stable afterwards. The AFI decreased significantly at 24, 48 and 72 hours. Conclusions: the use of high doses of nifedipine with tocolysis causes a decrease of the maternal's diastolic blood pressure and consequently decreases the amniotic fluid index, but probably without any clinical repercussions.
Resumo Objetivos: avaliar os efeitos da nifedipina utilizada na tocólise sobre os parâmetros maternos e fetais. Métodos: estudo de coorte incluindo 40 gestantes admitidas na enfermaria de alto risco para inibição do trabalho de parto prematuro entre setembro/2010 a maio/2012. Utilizou-se a nifedipina sublingual na dose de ataque de 20mg e uma manutenção de 20mg por via oral a cada seis e oito horas. As variáveis avaliadas foram os batimentos cardio-fetais (BCF), frequência cardíaca materna (FCM), pressão arterial sistólica (PAS) e diastólica (PAD) e índice de líquido amniótico (ILA). Todas as variáveis foram avaliadas antes da administração da nifedipina e aproximadamente após 6h e cada 24h até alta hospitalar. Resultados: não houve modificação dos BCF (p=0,48) e da PAS (p=0,29). A FCM aumentou após 24h, mas sem significância estatística (p=0,08) retornando a níveis similares ao da admissão com 48h. A PAD diminuiua partir de 6h (p = 0,04)até 72h, mantendo-se constante. O ILA diminuiu significativamente em 24h, 48h e 72h. Conclusão: a utilização de altas doses de nifedipina para tocóliseocasio na diminuição dos níveis pressóricos diastólicos maternos e consequentemente diminuição do ILA, mas provavelmente sem repercussões clínicas.
الموضوعات
Humans , Female , Pregnancy , Nifedipine/administration & dosage , Tocolysis/methods , Ultrasonography, Prenatal , Amniotic Fluid/diagnostic imaging , Obstetric Labor, Premature , Cohort Studies , Pregnancy, High-Riskالملخص
O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 22 artigos e 10 protocolos.
الموضوعات
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Disease Progression , Betacoronavirus/drug effects , Immunoglobulins/therapeutic use , Methylprednisolone/therapeutic use , Nifedipine/therapeutic use , Chloroquine/therapeutic use , Amlodipine/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Azithromycin/therapeutic use , Ritonavir/therapeutic use , Fluoroquinolones/therapeutic use , Drug Combinations , Lopinavir/therapeutic use , Interferon alpha-2/therapeutic use , Amoxicillin/therapeutic use , Hydroxychloroquine/therapeutic useالملخص
Abstract Background The human skin is an extremely sophisticated and evolved organ that covers the whole body. External agents or the patient's own diseases can cause skin injuries that can challenge healthcare professionals and impose high social, economic and emotional costs. Objectives To evaluate the impact of topical nifedipine on skin wound healing, specifically on polymorphonuclear cells, vascular proliferation, and collagen. Methods We used three pigs, and created eight injuries in the dorsal region of each animal. We applied 1%, 10%, and 20% concentration nifedipine creams to four of the wounds in animals 1, 2, and 3 respectively and treated the other twelve wounds with saline solution 0.9% only. We analyzed the presence of polymorphonuclear cells, vascular proliferation, and collagen at six different times (days 1, 3, 7, 14, 21, and 28). Results The evaluation of polymorphonuclear levels showed mild cell activity at all times in the control group, while in the nifedipine groups, marked levels were more frequent at all times during the experiment. There was a 4.84-fold increase in the chance of marked vascular proliferation (p = 0.019) and, at the same time, a decrease in collagen formation (OR 0.02 / p = 0.005) in animal 3. Conclusions Topical NFD may have an impact on skin wound healing mechanisms. Our study showed that polymorphonuclear cells and vascular proliferation increased. We also demonstrated that collagen formation decreased. Therefore, topical NFD may have a positive impact on skin wound healing. Additional studies are needed to confirm our results.
Resumo Contexto A pele humana é um órgão extremamente sofisticado e evoluído que cobre todo o corpo. As lesões cutâneas podem ser causadas por agentes externos ou pelas próprias doenças do paciente, e podem representar um desafio para os profissionais de saúde com altos custos sociais, econômicos e emocionais. Objetivos Avaliar o impacto da nifedipina tópica na cicatrização de feridas cutâneas, especialmente em relação a polimorfonucleares, proliferação vascular e colágeno. Métodos Utilizamos três porcos e realizamos oito ferimentos na região dorsal de cada animal. Aplicamos as concentrações de nifedipina creme a 1%, 10% e 20% para os animais 1, 2 e 3, respectivamente, sendo que, em quatro ferimentos, aplicamos o creme e, nos outros quatro ferimentos, apenas soro fisiológico a 0,9%. Analisamos a presença de polimorfonucleares, proliferação vascular e colágeno em seis momentos diferentes (dias 1, 3, 7, 14, 21 e 28). Resultados A avaliação dos níveis polimorfonucleares mostrou atividade celular discreta em todos os momentos no grupo controle, enquanto nos grupos nifedipina, os níveis marcados foram mais frequentes em todos os momentos do experimento. Houve aumento de 4,84 vezes na chance de uma produção marcada (p = 0,019) da proliferação vascular e, ao mesmo tempo, diminuição da formação do colágeno (odds ratio, OR 0,02; p = 0,005) no animal 3. Conclusões A nifedipina tópica pode ter impacto no mecanismo de cicatrização cutânea. Nosso estudo mostrou que há aumento dos polimorfonucleares e da proliferação vascular. Além disso, há diminuição da formação do colágeno. Assim, a nifedipina tópica pode ter impacto positivo na cicatrização das feridas cutâneas. Estudos adicionais são necessários para confirmar nossos resultados.
الموضوعات
Humans , Animals , Skin/injuries , Wound Healing/drug effects , Nifedipine/therapeutic use , Swine , Administration, Cutaneous , Nifedipine/administration & dosage , Collagen/blood , Models, Animalالملخص
A vasculopatia livedoide é uma doença rara caracterizada pela oclusão da microvasculatura da derme, originando lesões maculosas que, posteriormente, podem evoluir para úlceras e cicatrizes atróficas. Como um fenômeno vaso-oclusivo, o tratamento geralmente é realizado com antiplaquetários e fibrinolíticos. O presente relato descreve o caso de uma paciente refratária à terapia convencional, que obteve regressão da doença utilizando a rivaroxabana, um fármaco inibidor seletivo do fator Xa. (AU)
Livedoid vasculopathy is a rare disease characterized by occlusion of the dermis microvasculature, leading to spotted lesions that can later develop into ulcers and atrophic scars. As a vaso- occlusive phenomenon, treatment is usually performed with antiplatelet and fibrinolytic agents. The present report describes the case of a female patient refractory to conventional therapy who presented disease remission using rivaroxaban, a selective factor Xa inhibitor drug. (AU)
الموضوعات
Humans , Female , Middle Aged , Thrombosis/drug therapy , Skin Diseases, Vascular/drug therapy , Thrombotic Microangiopathies/drug therapy , Rivaroxaban/therapeutic use , Livedoid Vasculopathy , Paresthesia , Pentoxifylline/therapeutic use , Polyneuropathies/diagnosis , Thrombosis/complications , Vasodilator Agents/therapeutic use , Biopsy , Platelet Aggregation Inhibitors/therapeutic use , Nifedipine/therapeutic use , Fibromyalgia , Skin Diseases, Vascular/complications , Skin Diseases, Vascular/diagnosis , Connective Tissue Diseases/complications , Lower Extremity/injuries , Electromyography , Thrombotic Microangiopathies/complications , Factor Xa Inhibitors/therapeutic use , Foot/pathology , Diverticular Diseases , Smokers , Gabapentin/therapeutic use , Analgesics/therapeutic useالملخص
Abstract Objective: Myofibroblasts have been associated with the development of several pathologic fibrotic conditions. This longitudinal study aims to assess the proliferative and antiapoptotic effects of cyclosporin, nifedipine and phenytoin on gingival connective tissue cells of nonhuman primate, as well as to analyze a possible role of myofibroblasts in gingival overgrowth. Materials and Methods: Gingival samples from the right superior canine area were obtained from 12 male monkeys ( Sapajus spp ) to comprise the control group. After one week, the animals were randomly assigned to three groups, which received daily oral doses of cyclosporin, nifedipine or phenytoin for 120 days. Gingival samples were collected from the left superior canine area of two animals of each group at 52 and 120 days. Histological sections were stained with hematoxylin and eosin, and immunoreacted against α-SMA, Ki- 67 and bcl-2. Results: α-SMA immunoreaction was negative in the control and experimental groups. Similarly, no difference between groups concerning immunostaining against Ki-67 and bcl-2 was observed in connective tissue cells. Conclusion: Based on this methodology, it may be concluded that gingival overgrowths induced by cyclosporin, nifedipine and phenytoin are not associated with neither myofibroblast transdifferentiation, proliferation nor apoptosis of gingival connective cells in monkeys.
الموضوعات
Animals , Male , Phenytoin/pharmacology , Nifedipine/pharmacology , Cyclosporine/pharmacology , Cell Transdifferentiation/drug effects , Myofibroblasts/drug effects , Gingiva/cytology , Biopsy , Immunohistochemistry , Random Allocation , Longitudinal Studies , Actins/analysis , Haplorhini , Apoptosis/drug effects , Gingival Overgrowth/chemically induced , Gingival Overgrowth/pathology , Ki-67 Antigen/analysis , Ki-67 Antigen/drug effects , Genes, bcl-2/drug effects , Cell Proliferation/drug effects , Myofibroblasts/cytology , Gingiva/drug effectsالملخص
ABSTRACT Objective: To assess the efficacy and safety of atosiban in pregnant women with risk of preterm delivery as compared to nifedipine, indomethacin, terbutaline, fenoterol and placebo. Materials and methods: A systematic literature review was carried out in eight electronic databases, including Medline, Central, and Embase, using free and standardized search terms. Outcomes assessment included time delay until delivery, neonatal mortality, ratio of adverse maternal events, and ratio of neonatal complications. The quality of the evidence was evaluated per study and for the body of evidence and, whenever feasible, the information was synthesized into a meta-analysis. Alternatively, a narrative summary was presented. Results: Eleven studies were included. Atosiban did not show any statistically significant differences in terms of delaying delivery versus other uterine contraction inhibitors. The neonatal mortality was lower compared to indomethacin (RR = 0.21; 95% CI: 0.05 to 0.92), and the percentage of total maternal adverse events was lower compared to fenoterol (RR = 0.16; 95% CI: 0.08 to 0.31), nifedipine (RR = 0.48; 95% CI: 0.3 to 0.78), and terbutaline (RR = 0.44; 95% CI: 0.28 to 0.71). Conclusions: Atosiban has similar efficacy for delivery delay in patients with risk of preterm delivery as compared to other agents (moderate certainty), showing some advantages regarding neonatal mortality (low certainty) versus indomethacin, and compared to fenoterol, nifedipine and terbutaline in terms of maternal adverse events (moderate certainty).
RESUMEN Objetivo: evaluar la eficacia y seguridad de atosiban en gestantes con amenaza de parto pretérmino comparado con nifedipino, indometacina, terbutalina, fenoterol y placebo. Materiales y métodos: se realizó una revisión sistemática de la literatura en ocho bases de datos electrónicas (Medline, Central, Embase, entre otras), mediante términos de búsqueda libres y estandarizados. Los desenlaces evaluados incluyeron tiempo de retardo del parto, mortalidad neonatal, proporción de eventos adversos maternos y proporción de complicaciones neonatales. Se evaluó la calidad de la evidencia por estudio y para el cuerpo de evidencia, y se sintetizó la información mediante metaanálisis, cuando fue posible; de lo contrario, se resumió de forma narrativa. Resultados: se incluyeron once estudios. Atosiban no mostró diferencias estadísticamente significativas en retardo del parto contra otros uteroinhibidores. Mostró menor mortalidad neonatal que la indometacina (RR = 0,21; IC 95 %: 0,05 a 0,92), y menor proporción de eventos adversos maternos totales que el fenoterol (RR = 0,16; IC 95 %: 0,08 a 0,31), el nifedipino (RR = 0,48; IC 95 %: 0,3 a 0,78) y la terbutalina (RR = 0,44; IC 95 %: 0,28 a 0,71). Conclusiones: atosiban tiene una eficacia similar para retardar el parto ante la amenaza de un parto pretérmino con otros comparadores (certeza moderada), con ventajas frente a indometacina en mortalidad neonatal (certeza baja) y frente a fenoterol, nifedipino y terbutalina en eventos adversos maternos (certeza moderada).
الموضوعات
Humans , Obstetric Labor, Premature , Placebos , Terbutaline , Nifedipine , Indomethacin , Meta-Analysis , Fenoterolالملخص
<p><b>OBJECTIVE</b>Based on the western medication, to evaluate the advantages in the morning blood pressure treated with acupuncture at Fengchi (GB 20) and Neck-Jiaji (EX-B 2) combined with acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen in the patients with essential hypertension.</p><p><b>METHODS</b>A total of 90 patients of essential hypertension of the mild and moderate degrees were randomized into a medication group (30 cases, 3 dropping), No.1 acupuncture group (30 cases, 2 dropping) and No.2 acupuncture group (30 cases, 1 dropping). In the medication group, adalat was prescribed for oral administration, 30 mg at 7 am every day, continuously for 6 weeks. In the No.1 acupuncture group, on the basis of the treatment as the medication group, the acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen was applied and the acupoints were Renying (ST 9), Hegu (LI 4), Taichong (LR 3), Quchi (LI 11) and Zusanli (ST 36). In the No.2 acupuncture group, on the basis of the treatment as the No.1 acupuncture group, Fengchi (GB 20) and Neck-Jiaji (EX-B 2) were added in acupuncture. Acupuncture was given in the time zone from 8 am through 10 am every day, once a day, 5 times a week, totally for 6 weeks. Separately, before treatment and in 2, 4 and 6 weeks of treatment, the morning blood pressure, the control rate and the symptom score were observed in the patients of the three groups. The morning blood pressure was followed up in 3 and 6 months separately.</p><p><b>RESULTS</b>Compared with those before treatment, in 2, 4 and 6 weeks of treatment, the levels of blood pressure reduced in the patients of the three groups (<0.05, <0.01). After 2-week treatment, the differences were not significant in the morning blood pressure and its control rate in the patients of the three groups (all >0.05). In 4 and 6 weeks of treatment, the levels of the morning blood pressure in the No.2 acupuncture group were lower than those in the No.1 acupuncture group, and the results in the No.1 and No.2 acupuncture groups were all lower than those in the medication group (all <0.05). In the follow-up visit for 3 and 6 months separately, the differences were not significant in the morning blood pressure among the three groups (all >0.05). In 2, 4 and 6 weeks of treatment, the symptom scores reduced as compared with those before treatment in the three groups (all <0.05). The symptom scores in the No.1 and No.2 acupuncture groups were all lower than those in the medication group (all <0.05). The differences were not significant between the No.1 acupuncture group and the No.2 acupuncture group (all >0.05).</p><p><b>CONCLUSION</b>The comprehensive treatment of acupuncture at Fengchi (GB 20) and Neck-Jiaji (EX-B 2) combined with acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen achieve the effects of reducing the morning blood pressure in the patients with essential hypertension, relieving the symptoms of hypertension such as headache, vertigo and tinnitus and the effects are better than those of the acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen.</p>
الموضوعات
Humans , Acupuncture Points , Acupuncture Therapy , Blood Pressure , Combined Modality Therapy , Essential Hypertension , Therapeutics , Nifedipine , Therapeutic Uses , Treatment Outcomeالملخص
@#<p style="text-align: justify;"><strong>OBJECTIVE:</strong> To determine the risk of postpartum hemorrhage among patients who were treated with nifedipine for tocolysis of preterm labor.</p><p style="text-align: justify;"><strong>METHODS:</strong> A prospective cohort study was conducted with 66 pregnant women admitted for preterm labor. One group of women was given nifedipine to give time for the administration of corticosteroids for fetal lung maturity and/or control of preterm labor and another group was not given nifedipine as they were admitted in advanced stage of labor (ie, more than or equal to 4 cm cervical dilatation). Independent/paired sample t-test, Mann-Whitney U/Wilcoxon signed rank test, and Fisher's exact test were used to determine the difference of mean, median, and frequency between and within groups, respectively. STATA 12.0 was used for data analysis.</p><p style="text-align: justify;"><strong>RESULTS:</strong> There was more blood loss during delivery, which was statistically significant, among those who received nifedipine compared to those who have not taken the medicine (350 mL versus 250 mL, p = 0.021). Furthermore, the decreases in hemoglobin and hematocrit were also lower among those who did not receive nifedipine compared to those who received nifedipine for tocolysis (8.5 mg/dL versus 16.0 mg/dL, p = 0.014 and 0.03 versus 0.05, p = 0.010), again, statistically significant.</p><p style="text-align: justify;"><strong>CONCLUSION:</strong> Nifedipine used as tocolytic appear to increase blood loss during delivery, which was statistically significant. Greater amount of blood loss may be anticipated among those with nifedipine intake thus helping the obstetrician in preparing for active management of postpartum hemorrhage and preventing maternal morbidity and mortality.</p>
الموضوعات
Humans , Female , Nifedipine , Obstetric Labor, Premature , Postpartum Hemorrhage , Tocolytic Agentsالملخص
Preterm birth is a major cause of neonatal morbidity and mortality, and occurs in 5% to 15% of all pregnancies. Therefore, its prevention is a major opportunity to reduce medical costs and to promote public health in all countries. Preterm birth is a broad great obstetric syndrome that arises from a wide variety of causes. Although many therapeutic agents are used for premature labor, most of them have serious maternal side effects, and they are ineffective in cases when labor has already begun. Therefore, the authors would like to introduce progesterone, as a treatment to prevent preterm labor. We also investigated whether nifedipine, which is used to treat preterm labor, could prevent preterm labor. We are eager to find more effective and easier-to-use drugs to prevent preterm labor in the future.
الموضوعات
Female , Pregnancy , Mortality , Nifedipine , Obstetric Labor, Premature , Premature Birth , Preventive Medicine , Progesterone , Public Healthالملخص
Objetivo: evaluar los efectos de la progesterona vaginal combinada con nifedipino en comparación al uso único de Nifedipino en la amenaza de parto pretérmino en gestantes entre 24-34 semanas con longitud cervical ≤ a 25 mm en el Hospital Materno Infantil Germán Urquidi. Método: se realizó un estudio de cohorte, prospectivo, comparativo y analítico. Es un diseño de dos grupos (comparativos) donde la selección de pacientes se hizo de acuerdo a criterios de inclusión y exclusión, se evaluaron 231 pacientes. Resultados: el 67% de las pacientes que usaron progesterona más nifedipino resolvieron el evento de Amenaza de Parto Pretérmino en la primera hora en comparación al 50% de las pacientes que usaron solo nifedipino. Con la combinación de progesterona y nifedipino se controló en 1 hora el episodio de Amenaza de Parto Prematuro entre las 24 a 34 semanas de gestación, con el uso único de nifedipino, desde las 32 - 34 semanas existe un promedio de 2 horas en sobrepasar el episodio. Con solo nifedipino como tocolítico, el 80% de los pacientes verificaron parto a los 5 días. Solamente el 20% lograron sobrepasar los 10 días de latencia. La combinación progesterona y nifedipino logro que el 30% de las pacientes alcanzaran una latencia entre los 21-30 días, La edad gestacional al nacimiento con la combinación progesterona y Nifedipino alcanza en un 80% una edad menor o igual a 37 semanas 6 días. Conclusiones: La combinación de Progesterona vaginal más nifedipino, mejora sustancialmente el pronóstico neonatal en todos los resultados obtenidos, el uso único de nifedipino tiene menores efectos beneficiosos en esta investigación.
Objective: evaluate the effects of Vaginal Progesterone combined with nifedipine compared to the single use of nifedipine in the threat of preterm delivery in pregnant women between 24-34 weeks with cervical length ≤ 25mm in the Hospital Materno Infantil Germán Urquidi. Method: a prospective, comparative and analytical cohort study was conducted. It is a design of two groups (comparative) where the selection of patients was made according to inclusion and exclusion criteria, we evaluated 231 patients. Results: the time to exceed the Preterm Childbirth episode, 67% of the patients who used progesterone plus nifedipine resolved the event within the first hour compared to 50% of patients who used only nifedipine. With the combination of progesterone and nifedipine, the episode of Premature Birth Threat between 24 and 34 weeks of gestation was controlled within 1 hour, with the sole use of nifedipine, from 32-34 weeks there is an average of 2 hours in excess of episode. With only nifedipine as tocolytic, 80% of the patients verified delivery at 5 days. Only 20% were able to exceed 10 days of latency. The combination progesterone + nifedipine achieved that 30% of the patients reached a latency between 21-30 days, Gestational age at birth with the combination progesterone + nifedipino reaches 80% an age less than or equal to 37 weeks 6 days. Conclusions: the combination of vaginal progesterone plus nifedipine substantially improves the neonatal prognosis in all the results obtained, the use of nifedipine alone has less beneficial effects in this investigation.
الموضوعات
Humans , Female , Pregnancy , Progesterone , Nifedipine/administration & dosage , Obstetric Labor, Prematureالملخص
ABSTRACT This article reports the development and characterization of a nanoemulsion (NE) able to improve the cutaneous penetration of nifedipine. NE with nifedipine was development and characterized, presenting droplet size of 20 nm with low polydispersity index (IP<0.1), spherical shape without aggregation, pH compatible with typical skin levels and stability evaluated by seven months. In the permeation studies, a classical formulation based in an oil/water cream containing nifedipine was used for comparison with NE. Nanoemulsion promoted and improved the retention of nifedipine in the epidermis and dermis in relation to classical formulation. This promoting effect is related to the nanometric size of the droplets of the NE (20 nm), which give him a large superficial area, favoring the contact of the nanocarrier with the skin surface. The NE was efficient in promoting accumulation of nifedipine in the dermis, which is the site of vasodilation action. NE was not irritating according to the primary dermal irritation tests. NE is a promising release system to promote cutaneous penetration of nifedipine and can be used in the future in clinical trials to promote healing of lesions caused by peripheral vascular diseases.
الموضوعات
Nifedipine/analysis , Nanotechnology , Emulsions/administration & dosage , Skin Absorption , Wound Healingالملخص
The aim of this study was to evaluate the relaxant and anti-inflammatory effects of two thalidomide analogs as phosphodiesterase-4 (PDE-4) inhibitors in pregnant rat uterus. Uteri from Wistar female rats were isolated at 19 day of pregnancy. Uterine samples were used in functional studies to evaluate the inhibitory effects of the thalidomide analogs, methyl 3-(4-nitrophthalimido)-3-(3,4-dimethoxyphenyl)-propanoate (4NO2PDPMe) and methyl 3-(4-aminophthalimido)-3-(3,4-dimethoxyphenyl)-propanoate (4APDPMe), on prostaglandin-F2α (PGF2α)-induced phasic, K⁺-induced tonic, and Ca²⁺-induced contractions. Accumulation of cAMP was quantified in uterine homogenates by ELISA. Anti-inflammatory effect was assessed by using ELISA for determination of the pro-inflammatory cytokines tumor necrosis factor-α (TNFα) and interleukin (IL)-1β, and anti-inflammatory IL-10, from uterine explants stimulated with lipopolysaccharide (LPS). Nifedipine, forskolin and rolipram were used as positive controls where required. Both thalidomide analogs induced a significant inhibition of the uterine contractions induced by the pharmaco- and electro-mechanic stimuli. Nifedipine and forskolin were more potent than the analogs to inhibit the uterine contractility, but these were more potent than rolipram, and 4APDPMe was equieffective to nifedipine. Thalidomide analogs increased uterine cAMP-levels in a concentration-dependent manner. The LPS-induced TNFα and IL-1β uterine secretion was diminished in a concentration-dependent fashion by both analogs, whereas IL-10 secretion was increased significantly. The thalidomide analogs induced utero-relaxant and anti-inflammatory effects, which were associated with the increased cAMP levels as PDE-4 inhibitors in the pregnant rat uterus. Such properties place these thalidomide analogs as potentially safe and effective tocolytic agents in a field that urgently needs improved pharmacological treatments, as in cases of preterm labor.
الموضوعات
Animals , Female , Humans , Pregnancy , Rats , Colforsin , Cyclic Nucleotide Phosphodiesterases, Type 4 , Cytokines , Enzyme-Linked Immunosorbent Assay , Interleukin-10 , Interleukins , Necrosis , Nifedipine , Obstetric Labor, Premature , Phosphodiesterase 4 Inhibitors , Rolipram , Thalidomide , Tocolytic Agents , Uterine Contraction , Uterusالملخص
Objective: To assess the effectiveness of Nifedipine and Glyceryl trinitrate patch in prolonging the pregnancy for more than 48 hours
Methodology: This was a randomized control study. Fifty patients with preterm labour meeting the inclusion criteria were inducted in study and randomly allocated to the treatment group A [Nifedipine] and group B [Glyceryl trinitrate patch, GTN]. After taking consent from the patients, all the details were documented on a proforma and tocolysis was started with either of these tocolytics according to a preset protocol
Results: Nifedipine was found to be more effective than GTN, as prolongation of pregnancy beyond 48 hours was more frequent [74%] with nifedipine than GTN [40%] with P value <0.05 . Similarly prolongation beyond 7 days was also more frequent [32%] with nifedipine as compared with GTN [24%]. Most common adverse effect found with nifedipine was headache followed by palpitations and hypotension. GTN patch had a better side effect profile with most of the patients being asymptomatic. Fetal distress was noticed more in GTN group as compared with nifedipine
Conclusion: Nifedipine, as a tocolytic, is found to be more effective in pregnancy prolongation when compared with Glyceryl trinitrate but has frequent maternal adverse drug effects. Glyceryl trinitrate patch is well tolerated by the patients with preterm labour with relatively fewer side effects
الموضوعات
Humans , Female , Nitroglycerin/pharmacology , Nifedipine/pharmacology , Pregnancy , Pregnant Women , Nitroglycerin , Nifedipineالملخص
Adenosine 3',5'-cyclic monophosphate (cAMP) participates in the regulation of numerous cellular functions, including the Na(+)-K(+)-ATPase (sodium pump). Ouabain, used in the treatment of several heart diseases, is known to increase cAMP levels but its effects on the atrium are not understood. The aim of the present study was to examine the effect of ouabain on the regulation of atrial cAMP production and its roles in atrial endothelin-1 (ET-1) secretion in isolated perfused beating rabbit atria. Our results showed that ouabain (3.0 micromol/L) significantly increased atrial dynamics and cAMP levels during recovery period. The ouabain-increased atrial dynamics was blocked by KB-R7943 (3.0 micromol/L), an inhibitor for reverse mode of Na(+)-Ca(2+) exchangers (NCX), but did not by L-type Ca2+ channel blocker nifedipine (1.0 micromol/L) or protein kinase A (PKA) selective inhibitor H-89 (3.0 micromol/L). Ouabain also enhanced atrial intracellular cAMP production in response to forskolin and theophyline (100.0 micromol/L), an inhibitor of phosphodiesterase, potentiated the ouabain-induced increase in cAMP. Ouabain and 8-Bromo-cAMP (0.5 micromol/L) markedly increased atrial ET-1 secretion, which was blocked by H-89 and by PD98059 (30 micromol/L), an inhibitor of extracellular-signal-regulated kinase (ERK) without changing ouabain-induced atrial dynamics. Our results demonstrated that ouabain increases atrial cAMP levels and promotes atrial ET-1 secretion via the mitogen-activated protein kinase (MAPK)/ERK signaling pathway. These findings may explain the development of cardiac hypertrophy in response to digitalis-like compounds.
الموضوعات
8-Bromo Cyclic Adenosine Monophosphate , Adenosine , Cardiomegaly , Colforsin , Cyclic AMP-Dependent Protein Kinases , Endothelin-1 , Heart Diseases , Nifedipine , Ouabain , Phosphotransferases , Protein Kinasesالملخص
Early life neuronal exposure to environmental toxicants has been suggested to be an important etiology of neurodegenerative disease development. Perfluorohexanesulfonate (PFHxS), one of the major perfluoroalkyl compounds, is widely distributed environmental contaminants. We have reported that PFHxS induces neuronal apoptosis via ERK-mediated pathway. Imperatorin is a furanocoumarin found in various edible plants and has a wide range of pharmacological effects including neuroprotection. In this study, the effects of imperatorin on PFHxS-induced neuronal apoptosis and the underlying mechanisms are examined using cerebellar granule cells (CGC). CGC were isolated from seven-day old rats and were grown in culture for seven days. Caspase-3 activity and TUNEL staining were used to determine neuronal apoptosis. PFHxS-induced apoptosis of CGC was significantly reduced by imperatorin and PD98059, an ERK pathway inhibitor. PFHxS induced a persistent increase in intracellular calcium, which was significantly blocked by imperatorin, NMDA receptor antagonist, MK801 and the L-type voltage-dependent calcium channel blockers, diltiazem and nifedipine. The activation of caspase-3 by PFHxS was also inhibited by MK801, diltiazem and nifedipine. PFHxS-increased ERK activation was inhibited by imperatorin, MK801, diltiazem and nifedipine. Taken together, imperatorin protects CGC against PFHxS-induced apoptosis via inhibition of NMDA receptor/intracellular calcium-mediated ERK pathway.
الموضوعات
Animals , Rats , Apoptosis , Calcium , Calcium Channel Blockers , Caspase 3 , Diltiazem , Dizocilpine Maleate , In Situ Nick-End Labeling , MAP Kinase Signaling System , N-Methylaspartate , Neurodegenerative Diseases , Neurons , Neuroprotection , Nifedipine , Plants, Edibleالملخص
A hipertensão é uma doença crônica não transmissível e mais freqüente na população sendo o principal fator de risco para complicações cardiovasculares, tais como acidente vascular cerebral e infarto agudo do miocárdio. Na presente pesquisa estão sendo estudados os fármacos utilizados no tratamento da hipertensão mais especificamente, os bloqueadores do canal de cálcio do grupo diidropiridínicos: besilato de anlodipino, nifedipino e nimodipino. O objetivo desse trabalho foi verificar a estabilidade intrínseca dos fármacos besilato de anlodipino, nifedipino e nimodipino, para isto foram utilizadas as seguintes técnicas: testes indicativos de estabilidade utilizando as técnicas de espectrofotometria na região do Ultravioleta/Visível (UV/VIS) e Cromatografia em fase Líquida de Alta Eficiência (CLAE). Termogravimetria/ Termogravimetria Derivada (TG/DTG), Calorimetria Exploratória Diferencial (DSC), Difração de Raios X (DRX), Espectroscopia de absorção na região do Infravermelho com Transformada de Fourier (FTIR) e Microscopia Eletrônica de Varredura (MEV). Para o fármaco besilato de anlodipino (AB) pelo método de degradação forçada, analisado por espectrofotometria no UV/VIS, as condições para a análise espectrofotométrica foram metanol e água a uma proporção de (5:45 v/v) e a segunda diluição com água. A leitura foi efetuada a 364,4nm. A linearidade foi estabelecida na faixa de 40,0-65,0 µg/mL e o coeficiente de correlação foi (r) 0,9992. O método cromatográfico, mostrou o diferente comportamento das substâncias nifedipino e nimodipino diante dos meios básicos, ácido, neutro e oxidativo. As condições para a substância nifedipino foram coluna LiChrospher®100 RP-18 (5µm) Merck® fase móvel constituída por metanol e água (45:55v/v), fluxo 1.0 mL/min, tempo de retenção 5,1min, detecção UV a 234nm e vazão de 1.0 mL/min. Foi obtida uma linearidade no intervalo de 5.0-55.0 µg/mL coeficiente de correlação (r) =0,9964. E para a substância nimodipino foram coluna LiChrospher®100 RP-18 (5µm) Merck® fase móvel constituída por acetonitrila e água (55:45v/v), fluxo 1.0mL/min, tempo de retenção 5,8 min, detecção UV a 235 nm e vazão de 1.0mL/min. Foi obtida uma linearidade no intervalo de 5.0-55.0 µg/mL coeficiente de correlação (r) =0,9964. Os resultados obtidos das curvas TG/DTG e DSC mostraram o perfil da decomposição térmica das substâncias estudadas pela Calorimetria Exploratória Diferencial. A análise dos resultados de DRX e DSC mostraram que não há evidências de polimorfismo nessas substâncias. No entanto nas análises de Espectroscopia de absorção na região do infravermelho com Transformada de Fourier (FTIR) não foram encontradas diferenças significativas na matéria-prima e no padrão de referência. As análises de MEV permitiram observar a cristalinidade das substâncias estudadas
Hypertension is the most frequent non-communicable chronic disease in the population being the main factor of risk for cardiovascular complications, such as stroke and acute myocardial infarction. In this work, active pharmaceutical ingredients used to treat hypertension were studied, more specifically the blockers calcium channel dihydropyridine group: amlodipine besylate, nifedipine and nimodipine. The aim of this study was to determine the intrinsic stability of amlodipine besylate, nifedipine and nimodipine. For this purpose the following stability test techniques were used: UV/VIS spectrophotometry and chromatography Net phase High Performance. Thermogravimetry/Derivative Thermogravimetry (TG/ DTG), Differential Scanning Calorimetry (DSC), X-Ray Diffraction (XRD), Fourier Transformed Infrared absorption (FTIR) and Scanning Electron Microscopy (MEV). For drug amlodipine besylate (AB) by forced degradation method analyzed by spectrophotometry UV/VIS spectrophotometric conditions for the analysis were methanol and water at a ratio (5:45v/v) and the second dilution with water. The reading was made at 364,4nm. The linearity was established in the range of 40.0 to 65.0 mg/mL and the correlation coefficient was (r) 0.9992. The chromatographic method showed different behavior of nifedipine and nimodipine substances on the basic means, acid, neutral and oxidative. The conditions for nifedipine were LiChrospher®100 RP-18 column (5µm) Merck® mobile phase consisting of methanol and water (45:55v/v), flow 1.0 mL/min, retention time 5,1min, UV detection at 234 nm and flow of 1.0 mL/min. Linearity was obtained within the range of 5.0-55.0 mg/mL correlation coefficient (r) = 0.9964. And for nimodipine the parameters were: LiChrospher®100 RP-18 column (5µm) Merck® mobile phase consisted of acetonitrile: water (55:45v/v), flow 1.0 mL/min, retention time 5,8min, UV detection at 235nm and flow of 1.0 mL/min. The linearity was obtained within the range of 5.0- 55.0 mg/mL correlation coefficient (r) = 0.9964. The results of TG/DTG and DSC curves presented the profile of the thermal decomposition of the substances studied by DSC. The results of XRD and DSC presented no evidence of polymorphism in these analyzes, however, according to analyzes of absorption spectroscopy in the infrared (FTIR) there were no significant differences in the raw materials and standard reference. SEM analyzes allowed to observe the crystallinity of the studied substances